Nectar Lifesciences Limited (NECLIFE.NS)
INR 44.39
(1.95%)
INR 44.39
(1.95%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 6.15 Billion INR | -16.37% |
| 2022 | 7.36 Billion INR | -12.58% |
| 2021 | 8.42 Billion INR | -4.07% |
| 2020 | 8.77 Billion INR | 15.89% |
| 2019 | 7.57 Billion INR | -14.13% |
| 2018 | 8.82 Billion INR | -6.73% |
| 2017 | 9.45 Billion INR | 9.34% |
| 2016 | 8.64 Billion INR | -6.54% |
| 2015 | 9.25 Billion INR | 3.82% |
| 2014 | 8.91 Billion INR | 5.06% |
| 2013 | 8.48 Billion INR | -2.82% |
| 2012 | 8.73 Billion INR | -3.3% |
| 2011 | 9.02 Billion INR | 18.27% |
| 2010 | 7.63 Billion INR | 34.86% |
| 2009 | 5.66 Billion INR | -15.46% |
| 2008 | 6.69 Billion INR | 45.95% |
| 2007 | 4.58 Billion INR | 18.81% |
| 2006 | 3.86 Billion INR | 179.89% |
| 2005 | 1.37 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | 178.94 Million INR | -97.57% |
| 2023 Q2 | 6.61 Billion INR | 3595.29% |
| 2023 Q3 | 203.5 Million INR | -96.92% |
| 2023 Q4 | 6.15 Billion INR | 2925.6% |
| 2023 FY | 6.15 Billion INR | -16.37% |
| 2022 Q2 | 7.75 Billion INR | 4145.61% |
| 2022 Q4 | 7.36 Billion INR | 5058.99% |
| 2022 Q1 | 182.67 Million INR | -97.83% |
| 2022 Q3 | 142.71 Million INR | -98.16% |
| 2022 FY | 7.36 Billion INR | -12.58% |
| 2021 Q4 | 8.42 Billion INR | 5024.01% |
| 2021 Q1 | 259.95 Million INR | -97.04% |
| 2021 FY | 8.42 Billion INR | -4.07% |
| 2021 Q2 | 7.79 Billion INR | 2900.13% |
| 2021 Q3 | 164.35 Million INR | -97.89% |
| 2020 Q1 | 214.6 Million INR | -97.17% |
| 2020 FY | 8.77 Billion INR | 15.89% |
| 2020 Q2 | 7.55 Billion INR | 3420.51% |
| 2020 Q4 | 8.77 Billion INR | 323.36% |
| 2020 Q3 | 2.07 Billion INR | -72.55% |
| 2019 Q4 | 7.57 Billion INR | 302.41% |
| 2019 Q1 | 218.32 Million INR | -97.53% |
| 2019 FY | 7.57 Billion INR | -14.13% |
| 2019 Q2 | 7.59 Billion INR | 3377.34% |
| 2019 Q3 | 1.88 Billion INR | -75.2% |
| 2018 Q4 | 8.82 Billion INR | 0.0% |
| 2018 FY | 8.82 Billion INR | -6.73% |
| 2017 FY | 9.45 Billion INR | 9.34% |
| 2016 FY | 8.64 Billion INR | -6.54% |
| 2015 FY | 9.25 Billion INR | 3.82% |
| 2014 FY | 8.91 Billion INR | 5.06% |
| 2013 FY | 8.48 Billion INR | -2.82% |
| 2012 FY | 8.73 Billion INR | -3.3% |
| 2011 FY | 9.02 Billion INR | 18.27% |
| 2010 FY | 7.63 Billion INR | 34.86% |
| 2009 FY | 5.66 Billion INR | -15.46% |
| 2008 FY | 6.69 Billion INR | 45.95% |
| 2007 FY | 4.58 Billion INR | 18.81% |
| 2006 FY | 3.86 Billion INR | 179.89% |
| 2005 FY | 1.37 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 859.94 Million INR | -616.008% |
| Ind-Swift Limited | 9.5 Billion INR | 35.245% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -86.644% |
| Sakar Healthcare Limited | 790.93 Million INR | -678.482% |
| Aurobindo Pharma Limited | 3.69 Billion INR | -66.715% |
| Innova Captab Limited | 2.33 Billion INR | -163.836% |
| Divi's Laboratories Limited | -39.77 Billion INR | 115.482% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 222.84% |
| Morepen Laboratories Limited | -231.17 Million INR | 2763.493% |
| Mankind Pharma Limited | -1.74 Billion INR | 452.178% |
| Sequent Scientific Limited | 4.17 Billion INR | -47.352% |
| Wanbury Limited | 1.1 Billion INR | -456.781% |
| Laurus Labs Limited | 24.35 Billion INR | 74.721% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 316.604% |
| Alembic Limited | 66.9 Million INR | -9103.741% |
| Hikal Limited | 7.96 Billion INR | 22.715% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | -59.272% |
| Neuland Laboratories Limited | -214.05 Million INR | 2976.465% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -118.251% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 243.686% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 659.094% |
| Themis Medicare Limited | 764.96 Million INR | -704.916% |
| RPG Life Sciences Limited | -364.7 Million INR | 1788.32% |
| Zydus Lifesciences Limited | 3.91 Billion INR | -57.395% |
| Lupin Limited | 19.38 Billion INR | 68.237% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 2574.88% |
| Wockhardt Limited | 18.27 Billion INR | 66.298% |
| Vaishali Pharma Limited | 119.13 Million INR | -5068.341% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -135.74% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 542.994% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 77.256% |
| FDC Limited | -57.75 Million INR | 10761.627% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 52.317% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -5029.419% |
| Eris Lifesciences Limited | 13.8 Billion INR | 55.403% |
| Venus Remedies Limited | -267.7 Million INR | 2400.076% |
| ZIM Laboratories Limited | 983.6 Million INR | -525.994% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 631.833% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 1779.849% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 211.794% |
| Shilpa Medicare Limited | 9.06 Billion INR | 32.11% |
| Albert David Limited | -278.36 Million INR | 2311.921% |
| Ajanta Pharma Limited | -954.9 Million INR | 744.811% |
| Hester Biosciences Limited | 2.29 Billion INR | -168.791% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -4147.119% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 38.622% |
| Gufic Biosciences Limited | 3.19 Billion INR | -92.758% |
| Windlas Biotech Limited | -273.04 Million INR | 2355.092% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 362.236% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | -1969.13% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -530.993% |
| Granules India Limited | 9.28 Billion INR | 33.698% |
| Aarti Drugs Limited | 5.54 Billion INR | -10.974% |
| Bal Pharma Limited | 1.26 Billion INR | -387.298% |
| Alkem Laboratories Limited | -1.6 Billion INR | 482.584% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 108.496% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 4924.036% |
| Medicamen Biotech Limited | 160.31 Million INR | -3740.729% |
| Unichem Laboratories Limited | 931.91 Million INR | -560.714% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | -2577.868% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 33480.153% |
| Valiant Laboratories Limited | 649.9 Million INR | -847.42% |
| Orchid Pharma Limited | -1.31 Billion INR | 568.648% |
| Medico Remedies Limited | 78.67 Million INR | -7726.052% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 248.26% |
| Ipca Laboratories Limited | 11.41 Billion INR | 46.06% |
| Brooks Laboratories Limited | 49.48 Million INR | -12342.766% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -13224.323% |
| Piramal Enterprises Limited | 491.39 Billion INR | 98.747% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 80.656% |
| NATCO Pharma Limited | -5.81 Billion INR | 205.85% |
| Suven Life Sciences Limited | -1.63 Billion INR | 477.124% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -218.549% |
| Strides Pharma Science Limited | 23.25 Billion INR | 73.525% |
| Indoco Remedies Limited | 6.47 Billion INR | 4.926% |
| Alpa Laboratories Limited | 35.36 Million INR | -17311.71% |
| Lasa Supergenerics Limited | 205.79 Million INR | -2891.901% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 753.78% |